PACS Group (PACS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 revenue rose 11.5% YoY to $1,498.6M; net income increased 16.2% to $60.8M and Adjusted EBITDA grew 33.6% to $175.7M.
Same-store SNF revenue grew 6.4%, with occupancy and skilled mix improving; quarter-end operations totaled 355 facilities across 20 states.
FY 2026 revenue and Adjusted EBITDA guidance increased, including contributions from Florida and Texas acquisitions and near-term integration investment.
Financial highlights
Q3 revenue was $1,498.6M vs. $1,344.6M YoY; operating income was $99.7M vs. $86.3M, and net income was $60.8M vs. $52.3M.
Q3 diluted EPS was $0.37 vs. $0.32; Adjusted EPS was $0.63 vs. $0.46, up 37%.
Adjusted Net Income was $104.0M vs. $75.9M; Adjusted EBITDA was $175.7M vs. $131.5M, and Adjusted EBITDAR was $273.9M.
Nine-month revenue was $4,347.1M vs. $3,931.0M; net income was $217.8M vs. $131.7M, and Adjusted EBITDA was $512.8M vs. $363.0M.
Q3 cost of services rose 9.2% to $1.142B; G&A increased to $138.4M, including higher stock compensation and an executive accelerated-vesting charge.
Outlook and guidance
FY 2026 revenue guidance increased to $5.95B–$6.05B from $5.75B–$5.85B; midpoint implies ~13% growth over 2025.
Adjusted EBITDA guidance increased to $685M–$695M from $640M–$660M; midpoint implies ~37% growth over 2025.
Guidance includes partial-year contributions from 32 Florida facilities and 11 Texas operations, plus near-term integration investment.
Guidance includes $5M of Ohio retroactive quality incentive payments received in October; future state incentive payments remain uncertain in timing and amount.
Latest events from PACS Group
- Raised 2026 EBITDA guidance to $650M, driven by acquisitions, high occupancy, and operational excellence.PACS
2026 Jefferies Healthcare Services and Technology Conference - Q2 2026 revenue up 9.1% and net income up 49.8%, with guidance raised amid regulatory risks.PACS
Q2 2026 - Board elections, auditor ratification, and executive pay all approved without stockholder questions.PACS
AGM 2026 - Q1 2026 revenue up 11.2%, net income up 184%, and EBITDA guidance raised to $605–$625M.PACS
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.PACS
Proxy filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PACS
Proxy filing - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 2025 - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 2024